Proprietary ImmunoSEQ Platform Technology: Adaptive's core competitive advantage is its unique, high-resolution immunoSEQ sequencing platform, which provides an unparalleled view of the adaptive immune system by deeply profiling T-cell and B-cell receptors.

Vast Proprietary Immune Receptor Data Library: The company has amassed an extensive and growing proprietary dataset of immune receptor sequences, which is a valuable asset for developing new diagnostics, therapeutics, and understanding immune responses.

FDA-Cleared Diagnostic Products: Adaptive holds a significant lead with its FDA-cleared clonoSEQ assay for minimal residual disease (MRD) detection in multiple blood cancers, providing a validated and clinically actionable diagnostic solution.